• Fitness tied to lower risks for lung and colorectal cancer

    FIT data also show higher likelihood of survival after diagnosis.

  • Rectal cancer: capecitabine tops 5-FU in neoadjuvant chemoradiation

    Meta-analysis shows superiority on several counts.

  • ESTRO 2019 – Total neoadjuvant therapy for patients with locally-advanced rectal cancer: which is the better sequence of treatment?

    Two opposite total neoadjuvant therapy sequences were compared in the “pick the winner” CAO/ARO/AIO-12 study, a trial of the German Rectal Cancer Study Group

  • Early rectal cancer: when is local excision an option?

    A systematic review of 16 studies.

  • MRI criteria for "good-prognosis" patients in rectal cancer

    Distinguishes who can avoid preoperative chemotherapy.

  • Rectal cancer: short-course RT most cost-effective for locally advanced disease

    Preoperative use indicated barring need for presurgical tumor downstaging.

  • Northern Ireland's health department makes two major health protection declarations
    Northern Ireland's health department makes two major health protection declarations

    Announcements pertaining to HPV vaccination and bowel screening.

  • High-dose vitamin D3 for CRC: befuddling findings

    SUNSHINE trial shows potential benefit for high-dose vitamin D during chemotherapy.

  • Rectal cancer: optimal dose, surgical timing with neoadjuvant radiotherapy

    Delay of 4-8 weeks bests 1-week delay for survival, tumor regression.

  • Node+ rectal cancer: watchful waiting OK after nCRT complete response

    Similar 5-year distant metastasis-free survival vs node-negative patients.

  • CRC: ERAS program beneficial after laparoscopic surgery

    A meta-analysis of 13 studies.

  • mCRC: dual HER2-targeted therapy shows benefit in MyPathway

    40% response rate in KRAS wild-type, HER2-amplified disease.

  • Early-onset CRC has distinct clinical, molecular features

    Patients younger than 50 years more likely to have MIS and metastatic disease; fewer BRAF V600 mutations

  • LARC: neoadjuvant mFOLFOX6 found safe in multicenter study

    N stage downgraded in >50% of patients with locally advanced rectal cancer.

  • GI cancer: time to do more in tackling unintentional weight loss?

    Interventions needed to increase awareness.

  • Statin use tied to reduce risk for postcolonoscopy colorectal cancer

    PCCRC could account for up to 9% of all diagnosed colorectal cancers.

  • Cancer survivors: chronic opioid use more common in first few years

    Use more common in colorectal and lung cancer vs breast cancer.

  • Load more